(b) whether it is a feet that most of these companies are importing drugs and finished medicines from 'their principals and associates;

(c) if so, names of the companies and names of drugs|finished medicines imported by each during the last two years, year-wise;

(d) whether it is a fact that all such information is being provided to Government under Form-6 which is obligatory; and

(e) names of the companies who did not submit Form-6 during 1989, 1990 and 1991 and what action has been taken against each of them?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) To the extent information is available, names of major multinational drug companies operating in India are given in the Annexure.

(b) and (c) This information is not monitored by this Department.

(d) Form-c does not call for details Tegarding source of import, purchase etc.

(e) On the whole the response of industry in respect of furnishing the details as per form-6 has been luke warm.

Usage of Imported and Indigenous raw materials

1651. SHRIMATI KAILASHPATI: Will the PRIME MINISTER be pleased to state:

(a) whether Government have studied the usage of imported and indigenous raw materials by drug industry;

(b) if so. what is the position of Ten Major multinational drug companies like Carman Remedies, Glaxo, Hoechst, Wyeth, Sandoz etc.;

(c) what is the ratio between the usage of imported -and indigenous raw material on overall basis;

(d) whether it is a fact that Government have ignored this aspect while taking a decision on the liberalisation of drug policy;

(e) whether it is a fact that Ratio Parameter has not been implemented so far;

(f) if so, the reasons therefor; and

(g) what steps have been taken in this direction?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) and (e) to (d) Trie Drug Policy 1986 provides that for any formulation activity, the value of overall consumption of imported bulk drugs should not be more than 50 per cent of the overall value of indigenously produced bulk drugs consumed. This parameter is being strictly implemented while considering the proposals of all Companies in the organised sector.

(d) The Drug Policy is still under review.

Revision of Assessment of the Price of Vitamin-C

1652. SHRI MOHD. KHALEELUR RAHMAN:

SHRI ASHOK NATH VERMA:

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that discrepancy was found in the assessment of fixed assets which necessitated revision of BICP recommendations on the price of Vitamin-C recently;

(b) if so, what additions have been made by Government and on what account before revising the price;

(c) what was the period of which rate invoices were verified and what was the quantity of each input purchased at that rate;